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In 1971, Judah Folkman published in the “New England
Journal of Medicine” a hypothesis that tumor growth is
angiogenesis-dependent and that inhibition of angiogen-
esis could be therapeutic [1]. This article also introduced
the term antiangiogenesis to mean the prevention of
new vessel sprouts from being recruited by a tumor.
In the last 35 years, it has been estimated that > 200
companies have worked and are still working in the area
of angiogenesis and several of the compounds that mod-
ulate angiogenesis are currently being evaluated in clini-
cal trials. A list of approved antiangiogenic drugs
approved for clinical use is available in the Table 1.
Even if the majority of pre-clinical studies have shown
that the growth of all experimental tumors can be effec-
tively inhibited by various antiangiogenic agents, the
clinical benefits of antiangiogenic treatments are rela-
tively modest, and in the majority of cases, the drugs
merely slow down tumor progression and prolong survi-
val by only a few more months.
The most promising antiangiogenic agents that are in
clinical development at this moment include bevacizu-
mab, the humanized anti-monoclonal antibody anti-
VEGF approved for use in combination with cytotoxic
agents [2], as well as small molecules receptor tyrosine
kinase inhibitors (RTKIs), approved as single agents, and
including sunitinib, an oral inhibitor of VEGFR-2,
PDGFR, FlLT-3, and c-KIT, and sorafenib, an inhibitor
of the Faf/MEK/Erk and the VEGFR and PDGFR signal-
ing pathways. These agents are generally well tolerated,
but the treatments may be accompained by distinct
adverse effects, including hypertension and proteinuria.
In a communication in the 2003 ASCO Meeting, Hur-
witz and co-workers reported that bevacizumab/IFL (iri-
notecan/fluorouracil/leucovirin) combination led to a
significantly prolonged survival and had a better ability
to shrink tumors that IFL alone. These results led the
FDA to approve the use of bevacizumab in patients with
metastatic colorectal cancer and Hurwitz and co-work-
ers have published the results of this study in 2004 [3].
In December 2005, sorafenib received FDA approval for
the treatment of renal cell carcinoma [4] while sunitinib
received FDA approval in January 2006 for patients with
gastrointestinal stromal tumors (GIST) and advanced
kidney cancer [5,6].
Clinical studies have shown benefits in relapsed-free
survival for metastatic colorectal cancer, advanced non-
small cell lung cancer, renal cell carcinoma, hepatocellu-
lar carcinoma, metastatic breast cancer, GIST and in
glioblastoma [7,8], but overall survival benefit has not
yet been seen [9], with the exception of bevacizumab
treatment in renal cell carcinoma as a single agent [10],
or in metastatic breast cancer in combination with a
taxane chemotherapy [11].
The most impressive clinical response occurred in the
low dose bevacizumab plus chemotherapy with a statis-
tically significant median overall survival (21.5 months)
versus fluorouracil/leucovorin alone (13.9 months) or
high-dose bevacizumab plus fluorouracil/leuocovirin
(16.1 months) [12].
Autocrine VEGF signaling to promote malignant cell
survival is also a common feature in haematological
malignancies, suggesting that anti-VEGF/VEGFR tar-
geted therapy would promote direct killing of tumor
cells, as well as inhibit angiogenesis. VEGF-directed
therapy has been investigated also in hematological
malignancies, most commonly in acute myeloid leuke-
mia, myelodysplastic syndrome, and in non-Hodgkin
lymphoma.
Clinical trials involving anti-VEGF agents induce only
a modest improvement in overall survival, measurable in
weeks to just a few months, and various tumors respond
differently in human patients to these agents.
These two principal findings could depend by different
synergistic causes:
1) Lack of understanding of which patients will show
the benefit of these agents and occurrence of drug resis-
tance [9,13,14]. This is due to the absence of reliable
surrogate markers of angiogenesis and antiangiogenesis
to demonstrate the efficacy of antiangiogenic agents in
clinical trials and for the monitoring of these agents
[15].
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acquired genotype alterations, exhibiting aneuploidy,
abnormal multiple chromosomes, and aberrant chromo-
somal architecture [16]. It has been proposed that proxi-
mity of tumor cells and endothelial cells within the
tumor microenvironment may be responsible for the
genotype alterations [17]. Genetic alteration of endothe-
lial cells leads to altered antiangiogenic targets and
resistance.
3) Antiangiogenic therapies may sometimes promote
invasion and metastasis [18]. It has been demonstrated
that sunitinib, a multi-targeted receptor tyrosine kinase
inhibitor of VEGF and platelet derived growth factor
(PDGF) signaling and the anti-VEGFR-2 antibody
DC101 stimulated the invasive behavior of tumor cells
despite their inhibition of primary tumor growth and
increased overall survival in some cases [19,20].
4) Inherent or acquired resistance to anti-VEGF drugs
can occur in patients, leading in some cases to a lack of
response and in others to disease recurrence, although
discontinuation of the therapy at the time of progression
is a factor limiting the effectiveness of antiangiogenic
therapy [21]. In the meantime, prolonged VEGF leads to
vascular pruning and endothelial cell apoptosis, release
of cytokines by host cells, which may promote tumor
re-growth.
5) In most tumors, the vasculature is altered showing
increased permeability, vessel dilatation, decreased/
abnormal pericyte coverage and abnormal basement
membrane structure. While VEGF neutralization can
initially limit tumor proliferation due to its antiangio-
genic effect, it can also result in transient vascular nor-
malization with improved oxygenation and perfusion
[22], favouring drug delivery. However, in gliomas nor-
malization of the vascular bed involves restoration of
the blood-brain barrier, thereby hampering, instead of
enhancing, the delivery of therapeutic compounds to
tumor cells [23].
6) Prolonged VEGF inhibition increases local hypoxia
leading to systemic secretion of other angiogenic cyto-
kines, such as FGF-2 and SDF-1a, which may promote
cancer re-growth and metastasis [24]. An analysis of
human breast cancer biopsies revealed that late-stage
breast cancers expressed several angiogenic cytokines in
contrast to earlier stage lesions, which preferentially
expressed VEGF [25].
VEGF inhibitors are effective in the antiangiogenic
treatment, but genetic mutations, vascular changes,
Table 1 List of Antiangiogenic Drugs Approved for Clinical Use
Drug Target Company Indication
Avastin
(Bevacizumab)
VEGF Genentech mCRC, NSCLC, Advanced breast cancer
Erbitux
(Cetuximab)
EGFR Imclone mCRC & Head and Neck cancer
Vectibix
(Panitumumab)
EGFR Amgen mCRC
Lucentis
(Ranibizumab)
VEGF Genentech Wet Age-related macular regeneration
Macugen
(Pegaptanib)
VEGF OSI Pharmaceuticals Wet Age-related macular regeneration
Endostar
(Endostatin)
Angiogenesis inhibitor Shangdong Simcere Medgen Lung cancer
Sorafenib
(Nexavar)
VEGFR, PDGFR &
Raf
Bayer AG/Onyx Advanced RCC
Sunitinib
(Sutent)
VEGFR, PDGFR &
c-kit
Pfizer Advanced RCC & GIST
Thalomid
(Thalidomide)
Angiogenesis inhibitor Celgene Corporation Multiple Myeloma
Sorafenib
(Nexavar)
VEGFR, PDGFR &
c-kit
Bayer AG/Onyx Advanced RCC
Sunitinib
(Sutent)
PDGFR & VEGFR Pfizer Advanced RCC & GIST
Dasatinib
(Sprycel)
Bcr-Abl & Src Bristol-Myers Squibb Gleevec-resistant CML or Ph+ ALL
Lapatinib
(Tykerb)
EGFR & Her2/neu GlaxoSmithKline Advanced metastatic Her2+ breast cancer
Velcade
(Bortezomib)
Proteosome inhibitor Millenium Pharmaceuticals Multiple myeloma
Tarceva
(Erlotinib)
EGFR Genentech/OSI Lung cancer
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tion of invasion and metastasis, reduce their effective-
ness. Further clinical investigations are needed to
optimize antiangiogenic treatments in solid and hemato-
logical tumors management, as well as the identification
of reliable markers that predict the relapse and the
response to these therapies.
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